SCYX vs. ETTX, NBRV, ACIU, ORGO, AMRN, ANRO, SKYE, PGEN, SBTX, and NKTX
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Entasis Therapeutics (ETTX), Nabriva Therapeutics (NBRV), AC Immune (ACIU), Organogenesis (ORGO), Amarin (AMRN), Alto Neuroscience (ANRO), Skye Bioscience (SKYE), Precigen (PGEN), Silverback Therapeutics (SBTX), and Nkarta (NKTX). These companies are all part of the "medical" sector.
SCYNEXIS (NASDAQ:SCYX) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
SCYNEXIS presently has a consensus price target of $15.00, indicating a potential upside of 538.30%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Entasis Therapeutics.
SCYNEXIS received 409 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote.
In the previous week, SCYNEXIS had 3 more articles in the media than Entasis Therapeutics. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for Entasis Therapeutics. SCYNEXIS's average media sentiment score of 1.83 beat Entasis Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by company insiders. Comparatively, 6.5% of Entasis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
SCYNEXIS has higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
SCYNEXIS has a net margin of 72.18% compared to Entasis Therapeutics' net margin of 0.00%. SCYNEXIS's return on equity of 112.89% beat Entasis Therapeutics' return on equity.
Summary
SCYNEXIS beats Entasis Therapeutics on 15 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
